An Ascending Dose Comparison of MVT-100 to Definity in Healthy Volunteers

Inclusion Criteria:

• Adult subjects 19 years of age or older, male or female

• Female subjects must no longer have child-bearing potential (>1-year post menopauseor surgically sterilized), or must

• have a negative urine pregnancy test, and

• be using and continue to use for 30 days after the study a medically effectivemethod of contraception

• Adequate hematologic, renal and hepatic function, as defined by:

• Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

• Platelet count ≥ 100 x 109/L

• Hemoglobin ≥ 90 g/L

• Plasma creatinine< 1.5 x ULN

• Total bilirubin within normal limits (< 2.5 x ULN if Gilbert's syndrome)

• Aspartate transaminase (AST) and Alanine transaminase (ALT) < 2.5 x ULN

• Subject must be willing and able to understand the study and provide writtenInformed Consent to participate in the study

Exclusion Criteria:

• Myocardial infarction within six months prior to enrollment

• Unstable angina, NYHA Class II or greater congestive heart failure

• EKG evidence of uncontrolled arrhythmia or history of clinically significantarrhythmia within the past six months

• Clinically significant Chronic Obstructive Pulmonary Disease (COPD) or otherpulmonary condition that is not controlled by medication or requires oxygenfrequently or continuously

• A history of pulmonary emboli

• Known hypersensitivity to perflutren, DEFINITY® or other echo contrast agent

• Inability to remain supine for 60 minutes

• Oxygen saturation < 95% on room air

• History of allergic reaction attributed to compounds of similar chemical compositionto MVT-100 or DEFINITY® or soy or egg allergies (see Investigator's Brochure)

• Subject has received any investigational drug within thirty (30) days prior toenrollment into the study

• Inability to comply with study procedures

• Subjects with any medical condition deemed by the investigator to make the subjectinappropriate for participation